TP53 and neoplasm: Tumor analysis of multiple TP53 mutations showed that patients with TP53 mutations had longer median OS (18.1 months vs. 8.1 months, p = 0.004), significantly longer median progression-free survival (4.5 months vs. 1.4 months, p=0.03), and higher objective remission rate (ORR) (51.2% vs. 20.7%, p=0.01).